Sugi Predict

Sugi Predict / Compounds / SCHEMBL20340683

SCHEMBL20340683

SCHEMBL20340683

CC(C)[C@H](NC(=O)CCCCNC(=O)CCl)C(=O)N[C@@H](C)C(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CASP1 P29466 1/20 0.38
▸ HDAC3 O15379 1/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ HDAC9 Q9UKV0 1/20 0.37
▸ HDAC5 Q9UQL6 1/20 0.37
▸ FAAH O00519 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19681421 0.86 SMN1; SMN2 (0.42) EPHX2SMN1; SMN2ALDH1A1CASP1HDAC3
SCHEMBL17722921 0.86 EPHX2 (0.44) EPHX2SMN1; SMN2ALDH1A1CASP1HDAC3
SCHEMBL23436483 0.85 EPHX2 (0.36) EPHX2SMN1; SMN2ALDH1A1CASP1HDAC3
SCHEMBL26058186 0.85 SMN1; SMN2 (0.41) EPHX2SMN1; SMN2ALDH1A1CASP1HDAC3
SCHEMBL25008828 0.85 SMN1; SMN2 (0.41) EPHX2SMN1; SMN2ALDH1A1CASP1HDAC3
SCHEMBL20935395 0.82 CTSL (0.37) EPHX2SMN1; SMN2ALDH1A1CASP1HDAC3
SCHEMBL25826711 0.81 CASP1 (0.39) CASP1FAAH
SCHEMBL20349710 0.80 CASP1 (0.41) EPHX2CASP1HDAC3HDAC4HDAC1
SCHEMBL19776047 0.80 CASP1 (0.39) CASP1
SCHEMBL18272885 0.80 CASP1 (0.41) EPHX2CASP1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037378-B2 Variant CD58 domains and uses thereof NOVARTIS AG (CH) 2024-07-16 — — US disclosed
US-20230295322-A1 BINDING MOLECULES AGAINST BCMA AND USES THEREOF NOVARTIS AG (CH) 2023-09-21 — — US disclosed
US-20230126689-A1 ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES GO THERAPEUTICS, INC. (US) 2023-04-27 — — US disclosed
US-20220396631-A1 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF NOVARTIS AG (CH) 2022-12-15 — — US disclosed
US-11161911-B2 Anti-glyco-MUC1 antibodies and their uses GO THERAPEUTICS, INC. (US) 2021-11-02 — — US disclosed
US-20210139585-A1 CD19 BINDING MOLECULES AND USES THEREOF NOVARTIS AG (CH) 2021-05-13 — — US disclosed
US-10603389-B2 Anti-cMet antibody drug conjugates and methods for their use ABBVIE INC. (US) 2020-03-31 — — US disclosed
US-20190314518-A1 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE AbbVie Manufacturing Management Unlimited Company (IE) 2019-10-17 — — US disclosed
US-20190119400-A1 ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES GO THERAPEUTICS, INC. (US) 2019-04-25 — — US disclosed
US-20190105329-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC (US) 2019-04-11 — — US disclosed
US-20190099431-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC (US) 2019-04-04 — — US disclosed
US-10011657-B2 Anti-CS1 antibodies and antibody drug conjugates ABBVIE BIOTHERAPEUTICS INC. (US) 2018-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230126689-A1 ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES CD44, SIGLEC7, SIGLEC9 EPHX2 4035/4885SMN1; SMN2 3931/4885ALDH1A1 1192/4885
US-12037378-B2 Variant CD58 domains and uses thereof CD2, CD58, CD2BP2 EPHX2 2920/4885SMN1; SMN2 4176/4885ALDH1A1 2708/4885
US-20190105329-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE LRRC59, LRRC47, HACD3 EPHX2 3883/4885SMN1; SMN2 3228/4885ALDH1A1 3611/4885
US-20190099431-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE LRRC59, LRRC47, HACD3 EPHX2 3883/4885SMN1; SMN2 3228/4885ALDH1A1 3611/4885
US-20230295322-A1 BINDING MOLECULES AGAINST BCMA AND USES THEREOF EPCAM, CD40, BCR EPHX2 3018/4885SMN1; SMN2 4125/4885ALDH1A1 2738/4885
US-20190314518-A1 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE MMAB, HNMT, SHMT1 EPHX2 975/4885SMN1; SMN2 3035/4885ALDH1A1 3025/4885
US-20210139585-A1 CD19 BINDING MOLECULES AND USES THEREOF CD22, BCL9, CD2 EPHX2 1944/4885SMN1; SMN2 1981/4885ALDH1A1 3890/4885
US-10011657-B2 Anti-CS1 antibodies and antibody drug conjugates CD47, CSGALNACT1, CSE1L EPHX2 4285/4885SMN1; SMN2 1919/4885ALDH1A1 3782/4885
US-20220396631-A1 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF CD2, CD2BP2, CD22 EPHX2 3408/4885SMN1; SMN2 3271/4885ALDH1A1 3621/4885
US-11161911-B2 Anti-glyco-MUC1 antibodies and their uses MUC1, SIGLEC7, SIGLEC9 EPHX2 4824/4885SMN1; SMN2 4252/4885ALDH1A1 3328/4885
US-20190119400-A1 ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES MUC1, SIGLEC7, SIGLEC9 EPHX2 4824/4885SMN1; SMN2 4252/4885ALDH1A1 3328/4885
US-10603389-B2 Anti-cMet antibody drug conjugates and methods for their use MMAB, HNMT, SHMT1 EPHX2 975/4885SMN1; SMN2 3035/4885ALDH1A1 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.